Macimorelin
DCTPepD ID DCTPepD0079
Active Ingredients Macimorelin
Description An orally available synthetic mimetic of the growth hormone (GH) secretagogue ghrelin with potential anti-cachexia activity. Upon oral administration, macimorelin mimics endogenous ghrelin by stimulating appetite and binds to the growth hormone secretagogue receptor GHSR in the central nervous system, thereby mimicking the GH-releasing effects of ghrelin from the pituitary gland. Stimulation of GH secretion increases insulin-like growth factor-I (IGF-I) levels which may further stimulate protein synthesis. In addition, ghrelin reduces the production of pro-inflammatory cytokines, which may play a direct role in cancer-related loss of appetite.
Synonyms AEZS-130; D-Tryptophanamide,2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-; EP 1572; JMV 1843; Macimorelin; Solorel
Disease AGHD, Cancer Cachexia
Classification
Peptide and derivative
Structure Information
Molecular Formula C26H30N6O3
Molecular Weight 474.565
Active Sequence Xw
Sequence Length 2
Modification X=Aib
IUPAC Name (2R)-2-(2-amino-2-methylpropanamido)-3-(1H-indol-3-yl)-N-[(1R)-2-(1H-indol-3-yl)-1-formamidoethyl]propanamide
InChI InChI=1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1
InChI_Key UJVDJAPJQWZRFR-DHIUTWEWSA-N
SMILES O=C(N[C@@H](NC=O)CC1=CNC2=C1C=CC=C2)[C@H](NC(C(C)(N)C)=O)CC3=CNC4=C3C=CC=C4
External Codes
PubChem CID 9804938
DrugBank Accession Number DB13074
NCI Thesaurus Code C95123
UNII 8680B21W73 GSRS
CAS 381231-18-1
Drug approval
Drug indication
Indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin has investigated for use/treatment in Cancer Cachexia.
| Drug Name | Strength | Dosage Form/Route | Company | Marketing Status | Drug ID | Approval year |
|---|---|---|---|---|---|---|
| Macrilen | eq 60mg base/pouch | For Solution; Oral | Novo | Prescription | NDA: 205598 | 2017 |
| Ghryvelin (Previously Macimorelin Aeterna Zentaris) | 0.5 mg per kg body weight | Granules Dissolved; Oral | Consilient Health Limited | Prescription | EMEA/H/C/004660 | 2019 |
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT01614990 | Cancer Cachexia | Cancer Cachexia | Phase 2 | Treatment |
| NCT03844217 | Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers - The Macicop-Study | Polyuria-polydipsia Syndrome | Not Applicable | Diagnostic |
More clinical information is obtained from ClinicalTrials.gov.
